Objective: To assess the effectiveness of liver length measurement in predicting hemoglobin (Hb) Bart's disease among fetuses at risk at mid-pregnancy.
Introduction
Hemoglobin (Hb) Bart's disease (homozygous a-thalassemia-1) is the most common cause of hydrops fetalis in Southeast Asia. [1] [2] [3] At present, this disease is more prevalent in other parts of the world because of population migrations. Fetuses with this disorder are uniformly lethal. Nevertheless, prenatal diagnosis is imperative because serious maternal complications are often encountered in pregnant women with Hb Bart's hydrops fetalis, including severe preeclampsia, dystocia, postpartum hemorrhage due to placentomegaly and psychological burden for carrying a nonsurviving fetus to term. Therefore, early diagnosis and early termination of the pregnancy before development of hydrops is essential. At present, although several sonographic markers have been proven to be useful in predicting fetal Hb Bart's disease before hydropic changes occur, 4 ,5 the efficacy of liver measurement for this purpose has never been thoroughly evaluated. Surprisingly, although it has long been known that hepatomegaly associated with extramedullary erythropoiesis is always seen in hydropic fetuses due to Hb Bart's disease, it has never been tested whether liver length measurement is helpful in early prenatal detection of this disorder, in spite of its simplicity to measure. Theoretically, liver length measurement is particularly helpful in the prediction of severe anemia occurring in early gestation such as Hb Bart's disease as fetal anemia can develop in as early as 12 to 13 weeks of gestation. 6, 7 Roberts et al. 8 evaluated fetal liver length on 53 examinations conducted in 21 isoimmunized pregnancies and found that all fetuses with a Hb of <10.0 g per 100 ml had a liver length that was greater than the ninetieth percentile, suggesting that liver length is a useful indicator of the degree of fetal anemia in isoimmunized pregnancies. This is consistent with a preliminary report by Vintzileos et al. 9 Similarly, fetuses with Hb Bart's disease, which is associated with severe anemia from early gestation, seem to have hepatomegaly at the same time. Although the classic hydropic changes due to Hb Bart's disease are likely to occur after 20 weeks, 10 our experience of ultrasound examinations at 18 to 22 weeks suggests that fetal liver length measurement may be useful in distinguishing normal from affected pregnancies. We hypothesize that liver length measurement may be useful in identifying fetal Hb Bart's disease among fetuses at risk before the development of frank hydrops fetalis. The objective of this study was to evaluate the efficacy of liver length at midpregnancy in predicting fetal Hb Bart's disease.
Methods
This prospective diagnostic study was undertaken at the Maharaj Nakorn Chiang Mai Hospital (Department of Obstetrics and Gynecology, Chiang Mai University, Thailand), with approval of the research ethical committee. Pregnant women were recruited into the study with written informed consent. The inclusion criteria included the following: (1) singleton pregnancies at risk of having fetuses with Hb Bart's disease (both of the couples were carriers of a-thalassemia-1, based on PCR for Southeast Asian type); (2) gestational age of 18 to 22 weeks, based on a reliable last menstrual period or fetal sonographic biometry in the first half of pregnancy; and (3) known definite diagnosis of Hb Bart's disease or non-Hb Bart's disease, based on cordocentesis and fetal blood analysis with high-performance liquid chromatography. The exclusion criteria were as follows: (1) fetal anomalies or chromosomal abnormalities and (2) unknown final fetal diagnosis in terms of the presence or absence of Hb Bart's disease. All ultrasound examinations were performed just before cordocentesis by the authors, using a real-time scanner with Aloka SSD alpha-10 machine (Aloka Co, Tokyo, Japan) or GE Voluson E8 (GE Healthcare, Wauwatosa, WI, USA), equipped with a transabdominal curvilinear transducer of frequency 2 to 5 MHz. On ultrasound examination, liver length measurement, standard fetal biometry and anomaly screening were performed. The steps in liver length measurement were as follows: 8, 11 (1) The fetal upper abdomen at the level of the stomach was first demonstrated on an axial view and the liver was visualized as the most visible part of the abdomen. (2) To appropriately measure the right lobe of the liver, fine adjustment and rotating the transducer was performed to obtain the proper plane for measurement, and the aorta was first imaged in the longitudinal plane. The transducer is then moved parallel to this plane until the tip of the right lobe and the right hemidiaphragm were imaged. Occasionally, the transducer had to be tipped to visualize both the diaphragm and the right lobe of the liver. This was a coronal image of the abdomen. (3) Fetal liver length was measured from the region where the right margin of the heart was in contact with the hemidiaphragm (top of the right hemidiaphragm) to the tip of the right lobe. Liver length was measured by placing electronic calipers as shown in Figure 1 . The measurement usually took <5 min; 2 to 3 min in most cases. The three best measurements were digitally recorded in the computerized record form and subsequently averaged for analysis. In addition, middle cerebral artery peak systolic velocity (MCA-PSV) was also measured using a standard technique described elsewhere. 12 All cordocenteses were performed immediately after ultrasound examination. Baseline demographic and obstetric data of pregnant women were also recorded on the patient's digital record forms at the same time. The pregnant women were treated as standard antenatal care. Hepatomegaly or abnormally enlarged liver size was defined by a liver length larger than the cutoff value based on the receiver-operator characteristic curve. The stored data were subsequently analyzed for the efficacy of fetal liver length in predicting fetal Hb Bart's disease, using the statistical package for the social sciences (SPSS) version 17.0 (SPSS, Chicago, IL, USA).
For sample size estimation, to gain a confidence level of 95% for a detection rate of at least 60% and a maximum allowable error (precision) rate of 10%, the study should include affected fetuses of at least 48 cases. Measurement outcomes were presented as sensitivity, specificity, as well as positive and negative predictive values.
Results
Over the study period (June 2007 to February 2010), 355 pregnant women at risk for having fetuses with Hb Bart's disease were recruited into the study. Overall, 334 of them were sonographically measured for liver length at 18 to 22 weeks and underwent cordocentesis with the available final diagnosis. Of 334 fetuses, 87 were finally proven to be affected by Hb Bart's disease, and the remaining fetuses were unaffected. The mean maternal age (±s.d.) was 27.02±6.7 years (range: 13 to 48). The mean gestational age ( ± s.d.) was 19.87 ± 1.3 weeks (range: 18 to 22 weeks). Of them, 42.5% were nulliparous and 57.5% were multiparous. No serious maternal complications, such as pregnancy-induced hypertension, were observed at mid-pregnancy.
The receiver-operator characteristic curve of liver length in predicting Hb Bart's disease was analyzed as shown in Figure 2 . The area under curve was 0.922 (95% confidence interval: 0.890 to 0.954) and the best cutoff was at a liver length of 27.0 mm. The diagnostic indices of liver length measurement in differentiating fetuses with Hb Bart's disease from unaffected fetuses are summarized in Table 1 . The liver length had a sensitivity of 71.3% Liver length as a predictor of Hb Bart's disease S Luewan et al and a specificity of 95.5%. Overall, 24 fetuses (27.6%) had some degree of hydrops fetalis, such as minimal ascites or pleural effusion. Notably, of these, 20 showed hepatomegaly as well. When fetuses with hydrops fetalis were excluded, sensitivity decreased to 66.7%, whereas specificity remained the same, as presented in Table 1 . MCA-PSV, defined as abnormal if >1.5 MoM, had a sensitivity of 91.0% and a specificity of 98.2% as shown in Table 1 . When combined, liver length and MCA-PSV, considered abnormal if either of them was abnormal, the combination had a sensitivity of 96.2% and a specificity of 94.1%. When analyzed separately for a specific gestational week, the accuracy of liver length in prediction was not significantly different as shown in Table 2 .
Discussion
The fetal liver is a major site of hematopoiesis in the second trimester and is a primary site of extramedullary hematopoiesis in fetuses complicated by anemia, in particular Hb Bart's disease or Rh isoimmunization, leading to enlargement of the liver. 8 Therefore, measurement of fetal liver length can theoretically be useful in the diagnosis of fetal anemia owing to various causes. In spite of being known for a long time that hepatomegaly is closely associated with the degree of fetal anemia, no study on liver size in predicting fetal Hb Bart's disease has been reported. To our best knowledge, this is the first study in the evaluation of this simple and practical technique in differentiating affected from unaffected fetuses.
On the basis of a comparison of fetal liver length of 21 isoimmunized pregnancies and 350 measurements in normal pregnancies, Roberts et al. 8 found a good correlation between liver length and fetal Hb level (r ¼ 0.794, P<0.001) and between liver length and reticulocyte count (r ¼ 0.721, P<0.001). All fetuses with Hb <10.0 g per 100 ml had a liver length greater than the ninetieth percentile. They concluded that liver length measurement seems to be a useful indicator of the degree of fetal anemia in isoimmunized pregnancies. However, although our findings were consistent with those reported by Roberts et al., liver length measurement in our study was not as highly effective as seen in their report. This may be because of the fact that liver length at 18 to 22 weeks of gestation may be not as sensitive in differentiating affected from unaffected fetuses as in later pregnancy like in the report by Roberts et al. At mid-pregnancy, most fetuses with Hb Bart's disease do not develop hydropic changes, and fetal anemia may not be so severe at this stage of pregnancy. We believe that in advanced gestational age when fetal anemia becomes more severe, liver length is likely to have higher sensitivity and specificity in predicting anemia. Liver length as a predictor of Hb Bart's disease S Luewan et al Among pregnancies at risk, at mid-pregnancy, liver length can predict fetuses with Hb Bart's disease with a sensitivity of B70% and a specificity of 95%. A relatively high specificity indicates that normal liver length at 18 to 22 weeks reduces the probability of being affected by the disease and may obviate the need for invasive procedures to confirm normality, especially in case of no other sonomarkers such as cardiomegaly or placentomegaly, although follow-up sonographic examinations are still required. A sensitivity of 70% suggests that liver length measurement may not be a good screening tool in identifying affected fetuses when compared with MCA-PSV as indicated in this study, because 30% of the affected fetuses will be missed. However, this may be used as an adjunct to other ultrasound markers to gain confidence in predicting fetal anemia, especially in fetuses at risk. When combined with MCA-PSV, liver length may increase sensitivity, although it may slightly compromise specificity. Therefore, measurement of liver length should not be used as a primary tool in the diagnosis of fetal Hb Bart's disease, as several affected fetuses can be missed during diagnosis. Nevertheless, the measurement is simple and easy to be trained, and unlike MCA-PSV, it still seems to be helpful in general practice, especially in the area of high prevalence. This study demonstrated that liver length at different gestational ages during 18 to 22 weeks yields no significant difference in prediction. Therefore, for convenience in clinical use, the same cutoff (27 mm) may be used.
The strengths of this study include (1) a large sample size of pregnant women at risk and (2) the fact that the examiners were blind to the final diagnosis at the time of ultrasound examination, as the measurements were performed just before cordocentesis. Nevertheless, bias might have existed in the measurement of liver length. The measurement was not a completely blind method as the examiner could appreciate the morphology of the fetuses, especially cardiomegaly on sonographic imaging. Therefore, early hydropic signs in affected fetuses, such as cardiomegaly, could have been visible in some cases and the diagnosis of Hb Bart's disease in such fetuses might have been anticipated. Some other limitations should be mentioned, including that interobserver variation among the examiners was not tested. In addition, the measurement may sometimes be difficult in some cases in which the lower border of the liver was unclear and was not always easily discriminated from the surrounding structures, especially using ultrasound machines of earlier models.
In conclusion, liver length assessment at mid-pregnancy can be helpful in predicting fetuses affected by Hb Bart's disease, although the accuracy may be not excellent. Among couples at risk with normal liver size, the risk of having an affected child is much lower, whereas hepatomegaly places the fetuses to be at a higher risk. This information may help couples decide on whether to opt for further invasive diagnosis or a noninvasive approach, especially when used as an adjunct to other tests.
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